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Abstract
Background: Cortex Phellodendri (C. Phellodendri), the dried trunk bark of Phellodendron amurense Ruprecht, has
been known as a traditional herbal medicine, showing several bioactivities. However, antiviral activity of C. Phellodendri
aqueous extract (CP) not reported in detail, particularly aiming the prophylactic effectiveness.
Methods: In vitro CP antiviral activity evaluated against Influenza A virus (PR8), Vesicular Stomatitis Virus (VSV), Newcastle
Disease Virus (NDV), Herpes Simplex Virus (HSV), Coxsackie Virus (H3-GFP) and Enterovirus-71 (EV-71) infection on immune
(RAW264.7) and epithelial (HEK293T/HeLa) cells. Such antiviral effects were explained by the induction of antiviral state
which was determined by phosphorylation of signal molecules, secretion of IFNs and cytokines, and cellular antiviral
mRNA expression. Furthermore, Compounds present in the aqueous fractions confirmed by HPLC analysis and evaluated
their anti-viral activities. Additionally, in vivo protective effect of CP against divergent influenza A subtypes was
determined in a BALB/c mouse infection model.
Results: An effective dose of CP significantly reduced the virus replication both in immune and epithelial cells.
Mechanically, CP induced mRNA expression of anti-viral genes and cytokine secretion in both RAW264.7 and
HEK293T cells. Furthermore, the main compound identified was berberine, and shows promising antiviral properties
similar to CP. Finally, BALB/c mice treated with CP displayed higher protection levels against lethal doses of highly
pathogenic influenza A subtypes (H1N1, H5N2, H7N3 and H9N2).
Conclusion: CP including berberine play an immunomodulatory role with broad spectrum antiviral activity, due to
induction of antiviral state via type I IFN stimulation mechanism. Consequently, C. Phellodendri could be a potential
source for promising natural antivirals or to design other antiviral agents for animal and humans.
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Background
Several viruses cause malignant diseases worldwide, resul-
ting in significant mortality and economic losses. For in-
stance, Influenza A viruses are responsible for seasonal
epidemics and have caused three pandemics in the 20th
century (1918, 1957, and 1968) [1]. In addition, viral
diseases cause serious threats to livestock sector and ani-
mal welfare together with productivity losses, uncertain
food security and negative impacts on human health [2].
Although various prophylactic or therapeutic drugs
and vaccines have been developed to prevent and treat
viral diseases, the emergence of novel mutants or resistant
virus strains reduces their efficacy and lead to the public
health problems. Especially, with a view to provide effective
methods for preventing viral diseases, researches have been
attempted to identify novel materials with antiviral activi-
ties from natural or synthetic resources.
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Natural products are one of relevant sources for anti-
viral substances. Therefore, many screening efforts have
been made to identify antiviral substances from natural
sources with high efficacy, low toxicity and minor side
effects. Hence, treatments with herbal extracts having
antiviral activities may assist to recover many animals
through effective feed conversions and weight gains to
result better economic returns. Consequently, as an alter-
native to conventional chemical agents, a large number of
phytochemicals which containing extracts or pure sub-
stances from medical plants have been recognized as anti-
virals [3].
To identify potential antiviral agents, 200 natural oriental
herbal medicines were screened and among them, Cortex
Phellodendri (C. Phellodendri) found to display a wide
array of antiviral activities. C. Phellodendri (Huangbai
in Chinese), the dried bark of Phellodendron amurense
Ruprecht (Family: Rutaceae), is one of the 50 funda-
mental herbs of traditional Chinese medicine and has
been used against osteoarthritis, weight loss, obesity, diar-
rhea, diabetes, pneumonia and eye infections for a long
period of time [4]. This herb is widely found in China and
the Korean peninsula, and a wide range of primary scien-
tific articles are already available on the activities of
extracts of Phellodendron bark, although the underline
mechanisms in the therapeutic process remain unclear.
Further, the antiviral activity of C. Phellodendri has not
been scientifically described.
In this study, the antiviral activities of C. Phellodendri
aqueous extracts (CP) against wide array of viruses in
vitro and in vivo were evaluated. Additionally, the
immune-modulatory potential of C. Phellodendri which
regulates the antiviral immune response was confirmed.
Methods
Cells and viruses
RAW264.7 (ATCC® TIB-71™), HEK293T (ATCC® CRL-
11268™), HeLa (ATCC® CCL-2™) and MDCK (ATCC
CCL-34, NBL-2) cells were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Invitrogen, Carlsbad,
CA, USA) supplemented with 10 % fetal bovine serum
(FBS) (Gibco, Grand Island, NY, USA) and 1 % antibiotic-
antimycotic solution (Gibco, Grand Island, NY, USA)
at 37 °C with 5 % CO2. Green Fluorescent Protein (GFP)-
tagged Influenza A (A/PuertoRico/8/34(H1N1) (PR8-GFP),
Newcastle Disease Virus (NDV-GFP) and challenge viruses
of influenza A subtypes [{A/Aquaticbird/Korea/W81/
2005 (H5N2)}, {A/PR/8 /34(H1N1)}, {A/Aquaticbird/
Korea/W44/2005(H7N3)} and {A/Chicken /Korea/116/
2004(H9N2)}] were propagated in the allantoic fluid of
10-day-old chicken embryos. Vesicular Stomatitis Virus
(VSV-GFP), Herpes Simplex Virus (HSV-GFP) and En-
terovirus-71 (EV-71) were propagated on confluent Vero
cells (ATCC® CCL-81™) and Coxsackie virus (H3-GFP) was
propagated on confluent A549 (ATCC® CCL-185™) cells.
Plant materials and total aqueous extract preparation
Crude plant material, the dried bark of Phellodendron
amurense Ruprecht (specimen number: Phellodendron
amurense Rupr., PSNA200005151048; Department of
Pharmacology at Busan National University, Korea),
was purchased from Jaecheon Oriental Herbal Market
(Jaecheon, Korea) and verified by Professor Ki-Hwan Bae at
the College of Pharmacy, Chungnam National University.
Water-soluble herbal extract of C. Phellodendri was pre-
pared by Vitabio Corporation (Daejeon, Korea).
Determination of Effective Concentration (EC50) of Cortex
Phellodendri in vitro
The EC50 can be defined as the observed extract concen-
tration at which 50 % reduction in virus titer. To deter-
mine the EC50 values of CP against divergent viruses in
vitro, a modified GFP assay was developed using
RAW264.7, HEK293T and HeLa cell lines [5]. Raw264.7,
HEK293T and HeLa cells were cultured in 96-well plates
and after 12 h of incubation, the media was replaced
with 2-fold serially diluted CP from original stock
(0.1 mg/ml). At 12 h post-treatment (hpt), RAW264.7
cells were infected with PR8-GFP (MOI = 1.0), VSV-GFP
(MOI = 1.0) or NDV-GFP (MOI = 3.0); HEK293T cells
with VSV-GFP (MOI = 0.2) or HSV-GFP (MOI = 2.0);
and HeLa cells with H3-GFP (MOI = 3.0) or EV-71
(MOI = 0.5) using DMEM containing 1 % FBS. At 2 h
post-infection (hpi), the inocula were replaced with
DMEM (10 % FBS). GFP expression was measured at
24 hpi using Glomax multi-detection system (Promega,
WI, USA). EC50 values were calculated as the extract
concentration which yielded 50 % GFP expression or in
the EV-71, 50 % reduction in viral cytopathic effects
(CPE).
Cytotoxicity assay (CC50) of Cortex Phellodendri in vitro
The CC50 assay was performed in 72-well tissue culture
plates and the CC50 was determined through trypan blue
exclusion test as described previously [6]. Increasing
concentrations (0.1-16 μg/ml) of the extract were added
to 75–80 % confluent RAW264.7, HEK293T and HeLa
cell monolayers. After 24 h, the cell viability of each
treatment group was determined by trypan blue staining.
Concentrations of the extract plotted against the cell via-
bilities, and CC50 was calculated as the concentration of
the extract resulting 50 % cell viability.
Antiviral assays in Cortex Phellodendri-treated RAW264.7
and epithelial (HEK293T or HeLa) cells
Virus replication inhibition assay was performed using
the GFP viruses as described previously with some
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modifications [7]. RAW264.7 (12-well plates; 8 x 105 cells/
well), HEK293T and HeLa cells (6-well plates; 1 x 106
cells/well) were incubated at 37 °C for 12 h. For the pre-
treatment assay, DMEM alone (untreated and virus-only
groups), positive control; DMEM with 1000 U recombin-
ant mouse or human interferon-β (rmIFN-β or rhIFN-β,
Sigma, St. Louis, USA) and DMEM with 1.0 μg/ml of CP
were added to the cells. At 12 hpt, RAW264.7 cells were
infected with either PR8-GFP (MOI = 1.0), NDV-GFP
(MOI = 3.0) or VSV-GFP (MOI = 1.0) using DMEM sup-
plemented with 1 % FBS. HEK293T cells were infected
with VSV-GFP (MOI = 0.2) or HSV-GFP (MOI = 2.0).
HeLa cells were infected with H3-GFP (MOI = 3.0) or
EV-71 (MOI = 0.5). At 2 hpi, wells were gently washed
with PBS and replaced the media with DMEM (10 %
FBS). GFP expression or CPE, which reflects virus rep-
lication, was observed at 12 or 24 hpi under 200X mag-
nification. The cell viability and the virus titer were
determined at 12 or 24 hpi. GFP expression was mea-
sured at 24 hpi using Glomax multi-detection system
(Promega, Wisconsin, USA) according to the manufac-
turer’s instructions.
NDV-GFP mRNA expression in RAW 264.7 cells
Total mRNA from RAW264.7 cells infected with NDV-
GFP (MOI = 3.0) was extracted using the RNeasy Mini
Kit (Qiagen, Seoul, Korea) and cDNA was synthesized
using reverse transcriptase (Toyobo, Japan) according to
manufacturer’s protocol. Real-time polymerase chain
reaction (RT-PCR) was performed using gene specific
primers to determine the NDV-GFP mRNA expression
levels. For the NDV Matrix (M) gene, forward primer
was 5′-TCGAGICTGTACAATCTTGC-3′ and the reverse
primer was 5′- GTCCGAGCACATCACTGAGC-3′ [8].
For the GAPDH (housekeeping gene), the forward primer
was 5′-TGACCACAGTCCATG CCATC-3′ and the re-
verse primer was 5′-GACGGACACATTGGG GGTAG-3′
[9]. Equal amount of PCR products were run on 1.5 %
ethidium bromide agarose gels and visualized using GelDoc
Imaging System (Bio-Rad, Seoul, Korea). The relative
band intensity (RBI) of the M gene was compared with
GAPDH using Band Quantification Software (Bio-Rad,
Seoul, Korea).
Virus titration from Cortex Phellodendri-treated cell
supernatants or cells
Viral titers were determined with cell supernatants
(VSV-GFP and H3-GFP) or cells (PR8-GFP and HSV-GFP)
in Vero cells using a standard plaque assay. EV-71 titer
measured by the 50 % tissue culture infectious doses
(TCID50) using HeLa cells with some modifications. Briefly,
75–80 % confluent HeLa cells grown in 96-well micro-titer
plates were infected with 10-fold serial diluted supernatants
(50 μl/well) collected from the infected cells. At 2 hpi,
DMEM (10 % FBS) containing L-1-tosylamido-2-pheny-
lethyl chloromethyl ketone (TPCK) trypsin (Thermo Fisher
Scientific, Rockford, USA) was added to the infected wells
and incubated for another 2 days. CPE were observed daily
under 200X magnification, and the titers were determined
by TCID50.
Oral administration of Cortex Phellodendri and virus
challenge in BALB/c mice
Five-week-old 52 BALB/c mice (16 ± 1 g) were used to
conduct in vivo experiments (Table 1) For the survival
rate analysis, 40 mice were grouped in to 4 main groups
(n = 10), each containing 2 subgroups, control (n = 5)
and CP treated group (n = 5). For the lung virus titration
another 12 mice were grouped into 2 sub-groups, con-
trol (n = 6) and CP treated group (n = 6), and lung tissue
was extracted at 3 (n = 3) and 5 dpi (n = 3) from each
control and treated group. CP were orally administered
to the mice (0.8 μg/g body weight) in a total volume of
200 μl at 1, 3 and 5 days before infection. PBS (200 μl)
was orally administered to control groups mice. Treat-
ment and challenge experiments were conducted in an
approved BSL-2+ laboratory facility. Mice were intrana-
sally infected with 5 times 50 % minimum lethal dose
(MLD50) of H1N1, H5N2, H7N3 or H9N2 in 20 μl of
PBS per mouse. Body weight and survival were moni-
tored up to 13 dpi. Mice exhibiting more than 25 % body
weight loss were considered as an experimental end
point and were humanely killed. Animal study was con-
ducted under appropriate conditions with the approval
of the Institutional Animal Care and Use Committee of
Bioleaders Corporation, Daejeon, South Korea, Protocol
number: BSL-ABLS-13-008.
Table 1 Mouse groups of in vivo experiments
Virus Group Treatment Extract Dose
(μg/g body weight)
Experiment
H1N1 Control (n = 5) PBS - Survival rate
CP (n = 5) CP 0.8 Survival rate
H5N2 Control (n = 5) PBS - Survival rate
CP (n = 5) CP 0.8 Survival rate
H7N3 Control (n = 5) PBS - Survival rate
CP (n = 5) CP 0.8 Survival rate
H9N2 Control (n = 5) PBS - Survival rate
CP (n = 5) CP 0.8 Survival rate
H1N1 Control (n = 6)
3 dpi (n = 3),
5 dpi (n = 3)
PBS - Lung titration
CP (n = 6)
3 dpi (n = 3),
5 dpi (n = 3)
CP 0.8 Lung titration
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Determination of lung viral titers
Lung tissues from euthanized mice were collected aseptic-
ally, and lung viral titer was calculated by the Reed and
Muench method and expressed as Log10 TCID50/Lung. In
the modified hemagglutination assay (HA), instead of
turkey red blood cells (RBC), 0.5 % chicken RBC was used
and wells containing HA were scored as positive [10].
Detection of IFN-β and pro-inflammatory cytokines
Cells were treated with 1000 units/ml rmIFN-β or
rhIFN-β and 1.0 μg/ml CP in DMEM supplemented
with 10 % FBS or media alone, and then incubated at
37 °C with 5 % CO2. The supernatants were harvested at 0,
12 and 24 hpt. Using commercial ELISA kits, murine inter-
leukin (IL)-6, IL-12, tumor necrosis factor-alpha (TNF-α)
(BD Bioscience, USA), murine IFN-β (PBL Interferon
Source, USA), human IFN-β (TFB Inc., Tokyo, Japan)
and human IL-6 (Invitrogen, Carlsbad, California, USA)
were measured according to manufacturer’s protocol.
Determination of the effects of Cortex Phellodendri on
Type I IFN-related protein phosphorylation by Immunoblot
analysis
RAW264.7 cells were treated with DMEM alone (negative
control), DMEM with 100 ng/ml LPS (positive control),
or DMEM with 1.0 μg/ml CP, and cells were harvested at
0, 3, 6, 12, and 24 hpt. Cell pellets were washed with PBS
and whole cell lysates were subjected to SDS-PAGE fol-
lowed by standard immunoblotting with indicated anti-
bodies: anti-IRF3 (Abcam, #ab25950), anti-phospho-IRF3
(Ser396) (Cell Signaling, #4947), anti-p65 (Cell Signaling,
#4764S), anti-phospho-p65 (Cell Signaling, #3031S), anti-
STAT1 (Cell Signaling, #9175), anti-phospho-STAT1 (Cell
Signaling, #9167), anti-TBK1 (Cell Signaling, #3504S),
or anti-phospho-TBK1 (Cell Signaling, #5483S), anti-
p38 (Cell Signaling, #9212), anti-phospho-p38 (Cell
Signaling #4631S), anti-ERK (Cell Signaling, #9102),
anti-phospho-ERK (Cell Signaling, #9102S), or anti-β-
actin (Santa Cruz SC 47778).
Level of mRNA induction by Cortex Phellodendri in vitro
RAW264.7 or HEK293T cells were treated with DMEM
supplemented with media alone (negative control), DMEM
with 1000 units/ml rmIFN-β or rhIFN-β (positive control),
or DMEM with 1.0 μg/ml CP and the cells were harvested
at 0, 3, 6, 12, and 24 hpt. The total RNA isolation, cDNA
synthesis, and visualization of band intensity after PCR
were as previously described. Additionally, different cDNA
levels from HEK293T cells were measured by quantitative
RT- PCR (qRT-PCR) using a QuantiTech SYBR Green
PCR kit (Qiagen, Seoul, Korea) on a Mygenie96 thermal
block (Bioneer, Daejeon, Korea). The PCR primers are
listed in Tables 3 and 4.
HPLC analysis for chemical characterization of aqueous
plant extract of Cortex Phellodendri
The liquid chromatography-mass spectrometry (LC-MS)
analysis was performed on an Agilent 1200 Series high-
performance liquid chromatography (HPLC) (Agilent-
technologies CO, USA) connected to a linear ion trap
mass spectrometer 4000 QTRAP system (AB Sciex CO.,
Canada) equipped with an ESI TurboV source. Chroma-
tography was carried out on a column ZORBAX Eclipse
XDB-C18 (4.6 x 150 mm, I.D.-5 μm) (Agilent technologies
CO., USA). The mobile phase consisted of 1 % Formic
acid (Solvent A) and Acetonitrile (Solvent B) in the gra-
dient mode as follows : 0–8 min 0–25 % B; 8–12 min
25–35 % B; 12–17 min 35–50 % B; 17–25 min 50–100 % B;
25–28 min 100–0 % B at flow rate of 1.0 ml/min at 30 °C.
Conditions of the MS analysis were as follows: positive ion
mode, spectra range from m/z 100 to 500, nebulizer;
70.0 psi. Molecular weight identification of purified frac-
tion (PA-6) and berberine was carried out by electrospray
ionization mass spectrometry (ESI-MS).
Determination of antiviral characteristics of berberine
PA-6 antiviral activity and cytokine inducing ability was
further tested in immune (RAW264.7) cells using an ef-
fective dose (10.0 μg/ml). Inhibition of virus replication
(PR8-GFP) in RAW264.7 cells, virus titration and induc-
tion of cytokine secretion were monitored according to
the protocols described above sections.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software version 6 for Windows (GraphPad Software,
USA). Data are presented as the means ± standard devia-
tions (S.D.) and are representative of at least three inde-
pendent experiments. Differences between groups were
analyzed by analysis of variance (ANOVA). Unpaired t-
test was performed at each time points to compare the
control and NDV infected extract-treated groups. Re-
sults for percent initial body weight were also compared
by Student’s t test. Comparison of survival was done by
log-rank test using GraphPad Prism 6 version. P < 0.05
were regarded as significant.
Results
Inhibition of viral replication in Cortex Phellodendri-treated
RAW264.7 cells
In vitro antiviral effects of CP were evaluated by ob-
serving the amount of GFP expressed in the infected
cell to analyze the effect on RNA and DNA viral repli-
cations. RAW264.7 cells treated with CP exhibited a
marked reduction in GFP expression as compared to
the untreated groups against PR8-GFP (Fig. 1a), VSV-GFP
(Fig. 1b) and NDV-GFP (Fig. 1c). GFP expression was sig-
nificantly reduced in extract-treated cells compared to the
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untreated groups (data not shown), which correlated with
viral titers. CP treatment reduced the viral titers by 2.3-
and 2-fold against PR8-GFP and VSV-GFP, respectively
(Fig. 1a and b). Importantly, CP-treated cells had ≥ 70 %
cell viability within 24 hpi for all tested viruses com-
pared to untreated cells which had significantly higher
cell death following virus infection (Fig. 1a-c). M-gene
mRNA expression which represent the NDV virus rep-
lication, decreased time coarsely in extract treated cells
compared to untreated groups (Fig. 1c right panel).
These results indicate that the CP has potential to in-
hibit VSV-GFP, PR8-GFP and NDV-GFP replication in
RAW264.7 cells.
Inhibition of viral replication in Cortex Phellodendri-treated
HEK293T and HeLa cells
CP antiviral activity on non-immune epithelial cell lines
such as HEK293T and HeLa cells was determined. Upon
pre-treatment of the CP, HEK293T cells displayed marked
reduction in GFP expression and viral titers by 6- and 2.6-
fold against VSV-GFP and HSV-GFP, respectively, at 24
hpi compared to untreated groups (Fig. 2a and b). More-
over, CP antiviral activity in HeLa cells against H3-GFP
and EV-71 was determined. CP pre-treatment exhibited
markedly reduced H3-GFP expression and reduced viral
titers by 4.5-fold at 24 hpi together with significant reduc-
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Fig. 1 Cortex Phellodendri antiviral activities in RAW264.7 cells. RAW264.7 cells treated with media alone, 1.0 μg/ml CP, or 1000 unit/ml rmIFN-β
at 12 h prior to infection with a PR8-GFP or b VSV-GFP or c NDV-GFP at 1.0 MOI. Images were obtained at 12 hpi (200X magnification). Cell
viabilities were determined by trypan blue exclusion and presented as a percentage of the control (cells without treatment). The PR8-GFP and
VSV-GFP titer were determined by standard plaque assay. NDV M-gene mRNA expression was evaluated using gene specific PCR primers and all
the samples normalized using GAPDH. Cell viabilities are expressed as mean ± SD. Error bars indicate the range of values obtained from counting
in triplicate in three independent experiments (*P < 0.05 indicates a significant difference between groups)
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untreated group (Fig. 2c). Furthermore, EV-71 induced
CPE were markedly inhibited and upon pre-treatment
with the extract, a low level of viral replication was ob-
served (Fig. 2d). Collectively, it is also clear that the CP
has ability to suppress DNA or RNA viral replication in
epithelial cell lines.
EC50 and CC50 of Cortex Phellodendri extracts in vitro
As shown in Table 2, CP inhibited the replication of PR8-
GFP (MOI = 1.0), VSV-GFP (MOI = 1.0) and NDV-GFP
(MOI = 3.0) by 50 % at an EC50 of 0.89 ± 0.09 μg/ml,
0.71 ± 0.15 μg/ml and 0.57 ± 0.13 μg/ml, respectively in
RAW264.7 cells. Moreover, the aqueous extract inhibited
VSV-GFP (MOI = 0.2) and HSV-GFP (MOI = 2.0) repli-
cation by 50 %, showing EC50 of 0.63 ± 0.06 μg/ml and
0.83 ± 0.07 μg/ml, respectively in HEK293T cells. Addi-
tionally, observed EC50 against H3-GFP and EV-71 were
0.75 ± 0.12 μg/ml and 0.39 ± 0.07 μg/ml, respectively in
HeLa cells. According to the EC50 and considering its
effectiveness and convenience during the experiments,
1.0 μg/ml of CP were selected as the optimum dosage for









































































































































































Fig. 2 Cortex Phellodendri antiviral activities in HEK293T and HeLa cells. HEK293T and HeLa cells treated with media alone, 1.0 μg/ml CP, or 1000
unit/ml rhIFN-β at 12 h prior to infection with a VSV-GFP or b HSV-GFP or c H3-GFP or d EV-71 at 1.0, 1.0, 3.0 and 0.5 MOI, respectively. Images
were obtained at 24 hpi (200X magnification). The tests were performed in triplicate. Virus titrations are expressed as mean ± SD. Error bars indicate the
range of values obtained from two independent experiments. Cell viabilities were determined by trypan blue exclusion, presented as a percentage of
the control (cells without treatment). (*P < 0.05 indicates a significant difference between groups)
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CP had CC50 of 7.31 ± 0.12 μg/ml, 6.36 ± 0.06 μg/ml
and 8.06 ± 0.04 μg/ml in Raw264.7, HEK293T and HeLa
cells, respectively (Table 2). Importantly, CC50 of CP
were several magnitudes higher than the EC50 of tested
viruses in their respective cell lines. Selection indexes (SI)
of CP for PR8, VSV-GFP and NDV-GFP in RAW264.7
cells were 8.2, 10.2 and 12.8, respectively; for VSV-GFP
and HSV-GFP in HEK293T cells were 10.1 and 7.7, re-
spectively; and for H3-GFP and EV-71 in HeLa cells were
10.7 and 20.9, respectively. These results suggest that CP
is relatively non-toxic and could be expedient as a wide
prophylactic and/or therapeutic potentials.
Protection against influenza A virus infection by oral
administration of Cortex Phellodendri in Balb/c mice
Minimum effective dose (0.8 μg/g body weight) was
chosen based on our previous in vivo experimental experi-
ences with various other herbal extracts (Data not shown),
and groups of BALB/c mice were infected with lethal
doses (5MLD50) of H1N1, H5N2, H7N3 and H9N2.
Table 2 Determination of EC50 and CC50 of Cortex phellodendri in RAW264.7, HEK293T and HeLa cells
Cell Ec50 ± S.D.
b(μg/ml) CC50 ± S.D.
c
(μg/ml)PR8-GFP VSV-GFP NDV-GFP H3-GFP HSV-GFP EV-71
Raw264.7 0.89 ± 0.09 0.71 ± 0.15 0.57 ± 0.13 - - - 7.31 ± 0.12
HEK293T - 0.63 ± 0.06 - - 0.83 ± 0.07 - 6.36 ± 0.06
HeLa - - - 0.75 ± 0.12 - 0.39 ± 0.07a 8.06 ± 0.04
aEffective concentration for 50 % reduction in CPE
bEffective concentration for 50 % reduction in GFP expression

















































































































































Fig. 3 Oral administration of Cortex Phellodendri provides protection against lethal infection with divergent influenza A subtype in BALB/c mice.
CP were orally administered to 5-week-old female BALB/c mice (0.8 μg/g body weight) in a total volume of 200 μl at 1, 3 and 5 days before infection
with 5MLD50 a H1N1, b H5N2, c H7N3 and d H9N2 Influenza A subtypes. PBS (200 μl) was orally administered to control groups. Percent survival and
weight changes after challenge were recorded until 13 dpi. e Virus titers in lung tissues of H1N1 infected mice were measured by TCID50 at 3 and 5 dpi.
(*P < 0.05 indicates a significant difference between groups)
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Around 4 dpi, most of the control group mice exhibited
severe clinical signs of respiratory disease. Additionally,
mice showed obvious clinical signs, including decreased
activity, huddling, hunched posture, and ruffled fur. Fur-
ther, body weights were decreased progressively and the
control groups succumbed to death by 9 dpi for all of the
viruses tested. Strikingly, CP-treated mice showed ≤ 20 %
body weight loss between 5 and 7 dpi and began to re-
cover their lost weight by 8 dpi, returning to their normal
state by 13 dpi (Fig. 3). All the groups that were orally in-
oculated with the herbal extract had higher survival rates
(80 % survival for H1N1 and H5N2 and 60 % survival for
H7N3 and H9N2) than control group. Survived mice in
these groups did not show obvious clinical signs except
slight weight losses.
Lung tissues were collected from the H1N1-infected
experimental group to examine the ability of CP to in-
hibit viral replication in the lung. In the control group,
H1N1 replicated efficiently with viral titer of 4.19 and
5.34 log TCID50/Lung at 3 dpi and 5 dpi, respectively. In
comparison, the viral burdens in CP treated groups were
several folds lower than control group which had 2.3
and 1.9 log TCID50/Lung, at 3 dpi and 5 dpi, respectively
(Fig. 3e). These findings suggest that CP can induce suf-
ficient inhibition of viral replication in lung and pro-
moted the survival of mice against lethal infections of
diverse influenza A viruses.
Cortex Phellodendri extracts induced the secretion of IFN-β
or pro-inflammatory cytokine and activation of Type I IFN
signal molecules
To determine the effect of CP on inhibition of the viral
replication, the levels of Interferon-β (IFN-β) and pro-
inflammatory cytokines were measured in the CP-treated
cell supernatant of RAW264.7 and HEK293T cells (Fig. 4).
CP (1.0 μg/ml) induced high levels of secreted TNF-α, IL-6,
IL-12 and IFN-β, similar to the pattern observed in IFN-β
treated cells in RAW264.7 cells (Fig. 4a). Though IL-6 and
IFN-β secretion levels were lower than IFN-β treated cells,


























































































































































Fig. 4 Induction of cytokines and the phosphorylation of signal molecules present in the type I IFN pathway by Cortex Phellodendri in vitro.
a RAW264.7 and b HEK293T cells were treated with media alone, with 1000 unit/ml rmIFN-β or rhIFN-β, or with 1.0 μg/ml CP. IFN-β, IL-6,
TNF-α and IL-12 were measured by ELISA at 0, 12 and 24 hpt. The tests were performed in triplicate. The data shows representative means ± SD. (*P< 0.05
indicates a significant difference between groups). c Cells treated with LPS or CP were harvested at 0, 8, 12, and 24 hpt and subjected to
standard immunoblot analysis for type I IFN-related or NF-kB related protein phosphorylation. d Detection of contaminated endotoxin in CP
by Limulus Amebocyte Lysate (LAL) assay. (EU; endotoxin unit)
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and IFN-β (Fig. 4b). Consequently, these data indicated that
CP can mediate the antiviral responses in immune or
epithelial cells by triggering the expression of IFNs and
pro-inflammatory cytokines which may stimulate the
antiviral state in cells, playing a crucial role in inhibiting
viral replication.
Phosphorylation levels of IFN related signal molecules
and NF-kB activation related molecule (p65) were mea-
sured in CP-treated RAW264.7 cells to determine the type
I IFN signal transduction. As shown in Fig. 4c, CP signifi-
cantly up-regulated the IRF-3, STAT1, TBK1, p65, p38
and ERK phosphorylation, the main signaling molecules in
the type I IFN and NF-kB pathways. Especially the phos-
phorylation of IRF3, the key indicator of IFN signal trans-
duction was induced at 8 hpt, and this effect markedly
increased with the time (Fig. 4c). Furthermore, increased
STAT-1 phosphorylation indicates the transcriptional
activation of interferon-stimulating genes (ISGs) which
involved in controlling viral infection. Additionally, CP-
treated RAW264.7 cells obviously activated NF-kB (p65),
leading to strong secretion of pro-inflammatory cytokines.
CP was tested with LPS (positive control) using a Limulus
Amebocyte Lysate (LAL) assay. Only a trace amount of
endotoxin was found in CP (Fig. 4d), thus confirmed that
the induction of type I IFN and pro-inflammatory signaling
was not due to LPS stimulation.
Induction of antiviral gene expression by Cortex
Phellodendri
mRNA expression levels of different antiviral and ISGs
in RAW264.7 and HEK293T cells in response to CP
treatment were further investigated, and levels in CP-
treated cells (1.0 μg/ml) were similar to positive control
compared to non-treated cells (Fig. 5) (Primers are listed
in Tables 3 and 4). In RAW264.7 cells, time-dependent up-















































































































































































































ISG -15 ISG -56
IFN -β TNF-α
ISG -15 ISG -56
IL -6 Mx-1
0    3     6   12   24(hr)
Fig. 5 Induction of IFN-β, IFN-related and antiviral genes by Cortex Phellodendri in vitro. RAW264.7 and HEK293T cells were treated with media
alone, CP (1.0 μg/ml), or 1000 units/ml of rmIFN-β or rhIFN-β. Time-dependent changes in mRNA expression after treatment in a RAW264.7
and c HEK293T cells were confirmed by RT-PCR and qRT-PCR respectively. b RBI of IFN-β, IFN-α, TNF-α, IL-6, and IFN-related genes (Mx1, ISG15
and ISG56) were determined using the image analysis program and are shown as a bar graph. All the samples normalized using GAPDH. Error
bars indicate the range of values obtained from two independent experiments
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mRNA expression levels were observed in CP treated cells
similar to the patterns of positive control (Fig. 5a, b).
Moreover, most of the antiviral or inflammation related
gene transcription levels were up-regulated in HEK293T
cells (Fig. 5c). Especially, IFN-β, Mx1, GBP-1, IL-6, IL-8
and TNF-α mRNA expression levels at 12 hpt were in-
creased by 15-, 14-, 6-, 20-, 12- and 9-fold, respectively.
Additionally, extracts induced the transcription of ISGs,
such as ISG-15 and ISG-56 (23- and 35-fold), respectively
at 12 hpt compared to non-treated cells. The observed
patterns were similar to the pattern of the rhIFN-β-
treated control (Fig. 5c). As a result, CP has the cap-
acity to up-regulate IFN-β, ISGs and various antiviral
gene transcriptional levels and this activation may have
a direct relationship with the antiviral abilities of the
extract, which were observed in RAW264.7, HEK293T
and HeLa cells.
HPLC analysis of aqueous plant extract of Cortex
Phellodendri, identification of berbrine and effects of
berberine on virus replication
To investigate the critical components in CP, quantita-
tive analysis was carried out by a reversed-phase HPLC
method for the various fractions present in the CP and 6
fractions (PA-1, PA-2, PA-3, PA-4, PA-5 and PA-6) were
successfully purified. Among 6 fractions, PA-6 (berberine)
was detected at a wavelength and retention time of 280 nm
& 12.885 min respectively, and 47.7 μg/mL of PA-6 present
in 16.8 mg/mL (w/v) of CP (Fig. 6). The typical full-scan
ESI-MS analyses of berberine and PA-6 is described in
Additional file 1: Figure S1. These ESI-MS data compared
to those reported in the literature [11–13], and PA-6 was
identified as berberine. The antiviral effect of identified
fractions (PA-1 to PA-6) was tested in RAW264.7 cells.
An effective dose (10.0 μg/ml) was selected based on
our preliminary experiments on the efficacy of purified
fractions (Data not shown) and viral replication was ob-
served with PR8-GFP in response to pre-treatment of
various fractions. Remarkably, PA-6 inhibited the GFP ex-
pression compared to untreated groups and the viral titers
were reduced by 3-fold at 24 hpi (Fig. 6c). Additionally, to
find out whether PA-6 is the main compound in CP to
stimulate cytokine secretion, IFN-β, IL-6 and TNF-α levels
were measured after treatment of PA-6. Markedly, levels
of IFN-β and cytokines secretion increased in RAW264.7
cells (Fig. 6d). These results suggest that berberine which
is a major constituent of CP has the potential to inhibit
the virus replication by inducing the antiviral state in
the cells.
Discussion
In the present study, the broad spectrum antiviral activity
of medicinal herb C. Phellodendri both in vitro and in vivo
was evaluated to suggest the rationale for its immune-
modulatory and biological properties. C. Phellodendri has
been reported as a well-known source for the variety of
therapeutics with rare side effects after a dose [14], and in
the tested cell lines, CP also did not show any significant
cytotoxic effect. Moreover, the cell CC50 of CP was several
magnitudes higher than the EC50 of tested viruses and the
SI of the herb for various viruses indicate the higher safety
margin of the extract for therapeutic and/or prophylactic
purposes (Table 1).
In the present study, the CP inhibited the replication of
PR8-GFP (Fig. 1a), VSV-GFP (Figs. 1b and 2a), NDV-GFP
(Fig. 1c), HSV-GFP (Fig. 2b), H3-GFP (Fig. 2c) and EV-71
(Fig. 2d) in immune (RAW264.7) and epithelial (HEK293T
and HeLa) cells. Interestingly, oral administration of CP not
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only increased the survival rate of mice subjected to lethal
challenges with different influenza A virus subtypes includ-
ing H1N1, H5N2, H7N3 and H9N2 but also led to rapid
weight recovery (Fig. 3). Although CP-inoculated mice ini-
tially displayed little weight reduction, majority did not lose
more than 25 % of their body weight. However, all of the
mice in the control groups displayed more than 25 %
losses within 9 dpi. Collectively, it suggest that CP is
strong enough to inhibit the viral replication and pro-
moted the survival of mice against lethal infections of
diverse influenza A viruses.
Upon viral infection, host cells initially recognize the
virus infection and rapidly evoke the antiviral innate im-
mune responses including secretion of type I IFN and
pro-inflammatory cytokines [15]. Secreted IFNs and cy-
tokines induce an antiviral state which is important to
protect the host cells against invading viruses, as induc-
tion of antiviral state in early time of virus infection is
critical to control the spread and pathogenesis of viruses
[16]. In this study, CP induces an antiviral state via the
induction of type I IFN and pro-inflammatory cytokines
in vitro. To elucidate the delineate features of CP in
antiviral signaling, the effect of CP on the phosphoryl-
ation of IRF-3, p65, TBK1, STAT1, ERK and p38, the im-
portant regulatory molecules which present in the type I
IFN [17–20] and NF-kB [21, 22] signaling pathways were
studied and it shown to be up-regulated. Additionally,





Fig. 6 Chemical characterization of Cortex Phellodendri by HPLC analysis and effects of PA-6 on virus replication. a Chemical compounds in CP
was analyzed by the reversed-phase HPLC. b RAW264.7 cells treated with media alone, 1.0 μg/ml CP, 10.0 μg/ml PA-6, or 1000 unit/ml recombinant mouse
IFN-β at 12 h prior to infection with PR8-GFP (MOI = 1.0). GFP expression images were obtained at 12 and 24 hpi (200X magnification). c PR8-GFP titer was
determined by standard plaque assay. d Secreted cytokines of murine IFN-β, IL-6 and TNF-α measured by ELISA. Tests were performed in triplicate. The
data shows representative means ± SD. (*P< 0.05 indicates a significant difference between groups)
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and various antiviral genes. These findings confirm that
CP can induce the innate immune responses via type I
IFN and NF-kB signaling for controlling viral replication.
In this study, murine macrophages (Raw264.7) were
used to evaluate the antiviral effect of CP and also used
epithelial cells such as HEK293T or HeLa cells which
are very susceptible for viral replication. Recently, it is
acknowledged that HEK293T [23] and HeLa [24] cells
have less prominent pattern recognition receptors (PRRs),
chiefly Toll-like receptors (TLRs). Thus it could postulate
that CP may contain active components which can bind
or penetrate the cell membrane and those active compo-
nents may stimulate the cell surface PRRs, cytoplasmic
PRRs or both and ultimately, can induce the antiviral im-
mune responses in immune cell or epithelial cells. A bac-
terial endotoxin, LPS (or lipid A-associated protein) is a
known immunomodulator and is often a contaminant in
biological preparations. Therefore, it could speculate that
macrophage-stimulating properties of CP might be due
to contamination from bacterial endotoxin [25]. In this
study, CP was tested with LPS using a LAL assay and
was found only a trace amount of endotoxin (Fig. 4d), and
antiviral function of CP was not due to LPS stimulation.
The constituents of CP are numerous and diverse, in-
cluding aporphine alkaloids, protoberberine alkaloids,
flavonoids, berberine, oxyberberine, palmatine, isovanillin,
ferulic acid, limonin and various other molecules [4]. HPLC
analysis was conducted to identify different active com-
pounds present in the total aqueous fraction and found six
major peaks (Fig. 6a), and six fractions (PA-1 to PA-6)
which were successfully purified. Among six fractions, PA-6
was identified to have significant antiviral properties similar
to a CP and later confirmed as berberine (Fig. 6c). Berber-
ine has already been studied for its anticancer properties
[26], antibacterial activity [27], antifungal activity [28] and
antiviral activity [29]. Especially, it was reported that
berberine inhibit influenza viral replication by reducing
the viral neuraminidase activity, and reducing inflamma-
tory responses which induced by influenza virus through
inhibition of nitric oxide (NO) and repression of TNF-α
and monocyte chemoattractant protein 1 (MCP-1) gene
transcription [30]. Moreover, HB-13, a compound derived
from berberine, also inhibits HSV-1 and HSV-2 activity
[31, 32]. However, in the present study, the antiviral effects
of berberine was demonstrated with more specific mech-
anism via type I IFN stimulation. Consequently, antiviral
or immunomodulatory effects of CP could be due to the
cumulative effect of berberine or various other unknown
active compounds present in the extract.
Modern pharmacological researches have further con-
firmed that alkaloids of C. Phellodendri could be used
for treating many diseases. Among them, relationship
between mechanisms of antiviral effects and active com-
pounds including berberine should be required further
study. Furthermore, the question of how to address the
need for both individualizing (the basis of TCM) and
standardizing (the basis of modern pharmacology) the
treatments with C. Phellodendri must be settled. Once
these issues are resolved, the prospects will be exists for
widespread use of C. Phellodendri as a safe, effective,
and affordable form of healthcare.
Conclusion
The current study propose that pre-treatment of CP has
a broad spectrum of anti-viral functions against VSV-
GFP, PR8-GFP, NDV-GFP, HSV-GFP, H3-GFP and EV-
71 in vitro and against divergent influenza A subtypes of
H1N1, H5N2, H7N3 and H9N2 in vivo mouse model.
Moreover, our results describe a possible mode of CP
antiviral activity via the induction of type I IFN or pro-
inflammatory cytokines and the subsequent stimulation
of the antiviral state in the host cell. Additionally, active
components present in CP including berberine are im-
portant for the observed antiviral and immunomodulatory
properties. Thus, the use of C. Phellodendri as an orally
active antiviral agent, together with present vaccines or in-
dividually, has the potential to be an effective remedy in
both humans and livestock for prophylaxis applications.
Additional file
Additional file 1: Figure S1. Electrospray ionization mass spectra of
PA-6 and berberine. The molecular weight identification of PA-6 (A) and
berberine (B) was carried out by ESI-MS. (PPTX 145 kb)
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